Andrew Baum
Stock Analyst at Citigroup
(2.85)
# 1,775
Out of 4,711 analysts
58
Total ratings
70.73%
Success rate
13.04%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $55 → $60 | $57.33 | +4.66% | 10 | Nov 12, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $24.92 | +60.51% | 2 | Oct 25, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $140 → $130 | $98.05 | +32.59% | 11 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $175.58 | +22.45% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $675 → $895 | $767.76 | +16.57% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $11.91 | -16.04% | 3 | Oct 20, 2023 | |
| PFE Pfizer | Maintains: Neutral | $42 → $35 | $26.36 | +32.78% | 9 | Oct 16, 2023 | |
| GSK GSK | Downgrades: Neutral | n/a | $33.60 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Neutral
Price Target: $55 → $60
Current: $57.33
Upside: +4.66%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $24.92
Upside: +60.51%
Merck & Co.
Oct 25, 2024
Maintains: Buy
Price Target: $140 → $130
Current: $98.05
Upside: +32.59%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $175.58
Upside: +22.45%
Eli Lilly
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $767.76
Upside: +16.57%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $11.91
Upside: -16.04%
Pfizer
Oct 16, 2023
Maintains: Neutral
Price Target: $42 → $35
Current: $26.36
Upside: +32.78%
GSK
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $33.60
Upside: -